Here are what the editors at HealthDay consider to be the most important developments in Dermatology for August 2010. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Novel Targeted Therapy for Melanoma Shows Promise
WEDNESDAY, Aug. 25 (HealthDay News) -- Therapy targeting the V600E BRAF mutation found in many melanoma tumors can result in complete or partial tumor regression in most patients, according to a study in the Aug. 26 issue of the New England Journal of Medicine.
FDA Warns Against Use of Foot Tanner
WEDNESDAY, Aug. 25 (HealthDay News) -- The U.S. Food and Drug Administration has issued a warning to consumers about the possible risk of ultraviolet overdose with a portable foot tanning device due to shortcomings in labeling and manufacturing.
Adalimumab Found Effective, Safe in Psoriasis Subgroups
MONDAY, Aug. 23 (HealthDay News) -- Adalimumab is consistently efficacious in the treatment of moderate to severe psoriasis across patient subgroups, and there are no significant differences in the risk of serious adverse events between adalimumab- and placebo-treated patients across weight categories, according to a post hoc analysis of REVEAL trial data in the September issue of the Journal of the American Academy of Dermatology.
Forearm Anesthesia Technique Effective in Palm Procedure
MONDAY, Aug. 23 (HealthDay News) -- Prilocaine administered in the forearm provides effective anesthesia without adverse events or nerve damage among patients receiving botulinum toxin (BTX) for the treatment of palmar hyperhidrosis, according to a study in the September issue of the Journal of the American Academy of Dermatology.
In Androgenetic Alopecia, Early Cardiac Screening Important
FRIDAY, Aug. 20 (HealthDay News) -- Patients with early-onset androgenetic alopecia (AGA) have higher risk for cardiovascular disease and should be screened early to determine the need for preventive treatment, according to a study in the September issue of the Journal of the American Academy of Dermatology.
About Half of Dermatologists in U.S. Employ Dermatoscopy
FRIDAY, Aug. 20 (HealthDay News) -- About half of U.S. dermatologists use dermatoscopy, and they tend to be younger, involved in resident teaching, or trained in dermatoscopy, according to the results of a survey published in the September issue of the Journal of the American Academy of Dermatology.
Ipilimumab Linked to Survival Benefit in Melanoma
WEDNESDAY, Aug. 18 (HealthDay News) -- Ipilimumab may improve survival in patients with previously treated metastatic melanoma, but with risk of severe adverse events, according to research published in the Aug. 19 issue of the New England Journal of Medicine.
Basal Cell Carcinoma Risk Factors Identified
WEDNESDAY, Aug. 18 (HealthDay News) -- Individuals who have red hair, are of higher socioeconomic status, are relatively young upon initial basal cell carcinoma (BCC) diagnosis, and/or develop a BCC lesion on their upper extremities have an increased risk of developing multiple BCC lesions, according to a study in the August issue of the Archives of Dermatology.
Psoriasis Linked to Non-Light Beer and Mental Health Risks
TUESDAY, Aug. 17 (HealthDay News) -- The risk of psoriasis is increased for female non-light beer drinkers, and the skin condition in turn increases mental health risks, according to studies in the August issue of the Archives of Dermatology. Another study in the same issue found that narrowband ultraviolet-B (NB-UV-B) can increase serum vitamin D levels while clearing psoriasis.
Bone Marrow Transplant May Treat Blistering Disease
WEDNESDAY, Aug. 11 (HealthDay News) -- Allogeneic bone marrow transplantation may help children with recessive dystrophic epidermolysis bullosa by increasing the deposition of type VII collagen (C7), the lack of which characterizes the disease, according to research published in the Aug. 12 issue of the New England Journal of Medicine.
Industry-Funded Clinical Trials Yield More Positive Outcomes
TUESDAY, Aug. 3 (HealthDay News) -- Drug clinical trials supported by industry are more likely to produce favorable results than trials supported by government or nonprofit/nonfederal organizations, and they are less likely to be published within two years of the study being completed, according to research published in the Aug. 3 issue of the Annals of Internal Medicine.
Deodorant Sprays Can Damage Skin When Used Incorrectly
TUESDAY, Aug. 3 (HealthDay News) -- Deodorant sprays can cause skin-damaging cold burns if improperly applied, according to a case report published online Aug. 10 in Pediatrics.
Copyright © 2010 ScoutNews, LLC. All rights reserved.
|Previous: August 2010 Briefing - Cardiology||Next: August 2010 Briefing - Diabetes & Endocrinology|
Reader comments on this article are listed below. Review our comments policy.